Abstract
Introduction

Evidence for the role of angiogenesis in cancer biology was first suggested by Judah Folkman, who found that solid tumours remained dormant and limited in size in the absence of neovascularization [1]. This observation has driven further research directed at targeting angiogenesis as a means of halting tumour growth, which has resulted in the current therapeutic use of several angiogenesis inhibitors as anticancer agents
. Recently, several studies have investigated the quantification of angiogenic proteins in urine for use in cancer diagnosis and prognosis [7] [8] [9] [10] . [11] [12] [13] [14] . If urinary levels of VEGF can be accurately quantified, evaluation of this protein may potentially provide a convenient and non-invasive predictor of tumour behaviour and the overall angiogenic state of the host. However, as with any marker evaluated in biological specimens, the stability of VEGF in the urine between the time of sample collection and analysis is of concern. Often, initial studies of a marker report promising results but subsequent confirmatory studies of the same candidate marker conflict, potentially due to the use of unstandardized methods that lack reproducibility [15] . Few studies have investigated the role of variables that could potentially affect VEGF measurements in urine [16] . (Fig. 3) .
Vascular endothelial growth factor (VEGF) is a ubiquitous angiogenic protein that acts as a mitogenic stimulus on endothelial cells. Secretion of VEGF by tumour cells can be detected in various body fluids including blood, urine and saliva
Materials and methods
Specimen collection
Evaluation of protease inhibition in urine samples
Effect of altering urine pH
Effect of protease inhibitors on VEGF degradation between 3 and 24 hours
To determine whether the reduction of VEGF levels between 3 and 24 hr was due to the presence of urinary proteases, VEGF levels in samples with and without protease inhibitors were compared following 3 and 24 hrs of sitting on the bench top ( Fig. 4A and B 
